Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis

加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖

基本信息

  • 批准号:
    8302192
  • 负责人:
  • 金额:
    $ 40.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-01 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Clinical Oncology Research Career Development Program (CDP) at the University of California, Davis (UC Davis) will train junior faculty scholars to be independent, patient-oriented cancer researchers. The scholars will conduct translational research to develop laboratory-driven clinical trials designed to optimize novel therapeutic approaches based on the underlying molecular profiles of individual patient tumors or tumor types. The CDP will produce new faculty members from diverse backgrounds who are skilled leaders in team science. UC Davis is well-positioned to train the next generation of clinician scientists in oncology because of its outstanding patient care; long-standing and well-funded infrastructure in clinical-translational investigation (including cancer clinical trials), including our NCI-designated Cancer Center and NCRR-funded Clinical and Translational Science Center (CTSC); experience in laboratory-clinical correlative science; and established inter- and intra-institution consortia, among other resources. Upon successful completion of a three-year, salary-supported core curriculum, Scholars will receive a UC Davis Cancer Center Certificate in Clinical Cancer Research. We will combine key didactic, research, and career development components to produce independent and productive clinical oncology researchers over the course of a three-year program. We will accomplish our goals through the following specific aims: 1) 1) Offer a mentored, competency-based didactic curriculum so Scholars can integrate basic, translational, and clinical science knowledge to discover and/or evaluate more effective treatments for cancer that improve patient outcome; 2) Oversee individualized patient oriented research projects (investigator-initiated clinical trials) customized to the interests and needs of each CDP Scholar; and 3) Provide oversight of CDP Scholar training to ensure the progressive development of a high-quality "end-product": a fully competent interdisciplinary-oriented clinician scientist who can successfully conduct translational cancer clinical trials with investigational new agents or devices. The curriculum for the CDP will be guided by two research tracks in Basic/Translational and Clinical science. Each trainee will gain appropriate, integrated didactic and "hands-on" mentored research training following a plan supervised by two senior, independently funded faculty members (one Basic/Translational mentor and one Clinical mentor) to be able to successfully tackle research questions in one of these tracks. We have incorporated unique venues for training in team science and interdisciplinary research into the curriculum in order to take advantage of the strengths of other training programs at UC Davis, particularly those housed in the CTSC. Our overall goal is to develop successful, independent clinical cancer researchers who will be able to work in teams to develop and test new cancer treatments based upon their understanding of the complex mechanisms underlying cancer biology and how they manifest disease in individual patients as well as in broad populations. Thus, we need to make the clinician well-versed in the language of the laboratory scientist and vice-versa. The long-term success of our multidisciplinary approach to understanding and developing targeted treatments for oncologic disease critically depends upon the training of a new generation of multidisciplinary researchers who possess ideas and skills that go far beyond their initial disciplinary boundaries.
描述(由申请人提供):加州大学戴维斯分校(UC Davis)的临床肿瘤学研究职业发展计划(CDP)将培训初级教师学者成为独立的,以患者为导向的癌症研究人员。学者们将进行转化研究,以开发实验室驱动的临床试验,旨在根据个体患者肿瘤或肿瘤类型的潜在分子谱优化新型治疗方法。CDP将培养来自不同背景的新教师,他们是团队科学的熟练领导者。加州大学戴维斯分校处于良好的地位,培养下一代临床科学家在肿瘤学,因为其出色的病人护理;长期和资金充足的基础设施,在临床转化研究(包括癌症临床试验),包括我们的NCI指定的癌症中心和NCRR资助的临床和转化科学中心(CTSC);实验室-临床相关科学经验;并建立了机构间和机构内联合会等资源。在成功完成三年的工资支持的核心课程后,学者将获得加州大学戴维斯分校癌症中心临床癌症研究证书。我们将结合联合收割机关键的教学,研究和职业发展的组成部分,在三年计划的过程中产生独立和富有成效的临床肿瘤学研究人员。我们将通过以下具体目标来实现我们的目标:1)1)提供一个指导性的,基于能力的教学课程,使学者可以整合基础,翻译和临床科学知识,以发现和/或评估更有效的癌症治疗方法,改善患者的预后; 2)监督个性化的患者导向研究项目(由发起人发起的临床试验)根据每位CDP学者的兴趣和需求进行定制;以及3)监督CDP学者培训,以确保逐步开发高质量的“最终产品”:一个完全胜任的跨学科导向的临床科学家谁可以成功地进行转化癌症临床试验与研究新的代理或设备。CDP的课程将由基础/转化和临床科学的两个研究轨道指导。每个学员将获得适当的,综合的教学和“动手”指导的研究培训后,由两名高级,独立资助的教师(一个基本/翻译导师和一个临床导师)监督计划,能够成功地解决这些轨道之一的研究问题。我们已纳入团队科学和跨学科研究的培训课程的独特场所,以利用在加州大学戴维斯分校,特别是那些住在CTSC的其他培训计划的优势。我们的总体目标是培养成功的,独立的临床癌症研究人员,他们将能够在团队中工作,开发和测试新的癌症治疗方法,基于他们对癌症生物学的复杂机制的理解,以及他们如何在个体患者和广泛人群中表现出疾病。因此,我们需要使临床医生精通实验室科学家的语言,反之亦然。我们的多学科方法理解和开发肿瘤疾病的靶向治疗的长期成功关键取决于新一代多学科研究人员的培训,他们拥有远远超出其最初学科界限的想法和技能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PRIMO N. LARA其他文献

PRIMO N. LARA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PRIMO N. LARA', 18)}}的其他基金

Phase I Molecular and Clinical Pharmacodynamic Trials ETCTN
I 期分子和临床药效试验 ETCTN
  • 批准号:
    9095678
  • 财政年份:
    2014
  • 资助金额:
    $ 40.92万
  • 项目类别:
A Correlative Biomarker Analysis for A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory NHL
来那度胺和博纳吐单抗联合治疗复发或难治性 NHL 患者的 I 期试验的相关生物标志物分析
  • 批准号:
    10192396
  • 财政年份:
    2014
  • 资助金额:
    $ 40.92万
  • 项目类别:
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program
加州大学戴维斯分校 Paul Calabresi K12 临床肿瘤学研究职业发展计划
  • 批准号:
    10681247
  • 财政年份:
    2011
  • 资助金额:
    $ 40.92万
  • 项目类别:
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis
加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖
  • 批准号:
    8918454
  • 财政年份:
    2011
  • 资助金额:
    $ 40.92万
  • 项目类别:
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis
加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖
  • 批准号:
    8090131
  • 财政年份:
    2011
  • 资助金额:
    $ 40.92万
  • 项目类别:
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis
加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖
  • 批准号:
    9336795
  • 财政年份:
    2011
  • 资助金额:
    $ 40.92万
  • 项目类别:
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program
加州大学戴维斯分校 Paul Calabresi K12 临床肿瘤学研究职业发展计划
  • 批准号:
    10195476
  • 财政年份:
    2011
  • 资助金额:
    $ 40.92万
  • 项目类别:
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program
加州大学戴维斯分校 Paul Calabresi K12 临床肿瘤学研究职业发展计划
  • 批准号:
    10429982
  • 财政年份:
    2011
  • 资助金额:
    $ 40.92万
  • 项目类别:
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis
加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖
  • 批准号:
    8518259
  • 财政年份:
    2011
  • 资助金额:
    $ 40.92万
  • 项目类别:
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis
加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖
  • 批准号:
    10018465
  • 财政年份:
    2009
  • 资助金额:
    $ 40.92万
  • 项目类别:

相似海外基金

Collaborative Research: Assessing the causes of the pyrosome invasion and persistence in the California Current Ecosystem
合作研究:评估加州海流生态系统中火体入侵和持续存在的原因
  • 批准号:
    2329559
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Standard Grant
Collaborative Research: RUI: Glacier resilience during the Holocene and late Pleistocene in northern California
合作研究:RUI:北加州全新世和晚更新世期间的冰川恢复力
  • 批准号:
    2303409
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Standard Grant
Conference: Southern California Geometric Analysis Seminar
会议:南加州几何分析研讨会
  • 批准号:
    2406732
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Standard Grant
LSAMP BD: UC Santa Barbara California Alliance for Minority Participation
LSAMP BD:加州大学圣塔芭芭拉分校加州少数族裔参与联盟
  • 批准号:
    2404971
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Standard Grant
BRC-BIO: The origin and genetic makeup of rare plants: bridging micro- and macroevolution in the California Floristic Province
BRC-BIO:稀有植物的起源和基因组成:连接加州植物省的微观和宏观进化
  • 批准号:
    2334849
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Standard Grant
RUI: Collaborative Research: Assessing the causes of the pyrosome invasion and persistence in the California Current Ecosystem
RUI:合作研究:评估加州当前生态系统中火体入侵和持续存在的原因
  • 批准号:
    2329561
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Standard Grant
CC* Regional Computing: The California State University System Technology Infrastructure for Data Exploration
CC* 区域计算:加州州立大学数据探索系统技术基础设施
  • 批准号:
    2346701
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Standard Grant
Collaborative Research: RUI: Glacier resilience during the Holocene and late Pleistocene in northern California
合作研究:RUI:北加州全新世和晚更新世期间的冰川恢复力
  • 批准号:
    2303408
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Standard Grant
The Incoherent Scatter Radar Community and Research Workshop; San Diego, California; June 2024
非相干散射雷达社区和研究研讨会;
  • 批准号:
    2426312
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Standard Grant
Collaborative Research: Improving Upper Division Physics Education and Strengthening Student Research Opportunities at 14 HSIs in California
合作研究:改善加州 14 所 HSI 的高年级物理教育并加强学生研究机会
  • 批准号:
    2345092
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了